{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:07:09Z","timestamp":1793830029395,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T00:00:00Z","timestamp":1446422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1843-3","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T16:39:41Z","timestamp":1446482381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand"],"prefix":"10.1186","volume":"15","author":[{"given":"Alice","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Obertov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Karunasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Lawrenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"1843_CR1","volume-title":"Cancer: new registrations and deaths 2011","author":"Ministry of Health","year":"2014","unstructured":"Ministry of Health. Cancer: new registrations and deaths 2011. Wellington: Ministry of Health; 2014."},{"issue":"2","key":"1843_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238\u201344.","journal-title":"JAMA"},{"issue":"11","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/cncr.28594","volume":"120","author":"M Roach 3rd","year":"2014","unstructured":"Roach 3rd M. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014;120(11):1620\u20139.","journal-title":"Cancer"},{"issue":"10","key":"1843_CR4","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.clon.2014.06.016","volume":"26","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N. Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R Coll Radiol). 2014;26(10):e21\u201346.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"12","key":"1843_CR5","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","volume":"24","author":"UE Studer","year":"2006","unstructured":"Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868\u201376.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1843_CR6","doi-asserted-by":"publisher","first-page":"R305","DOI":"10.1677\/ERC-10-0187","volume":"17","author":"N Sharifi","year":"2010","unstructured":"Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010;17(4):R305\u201315.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1843_CR7","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1843_CR8","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388\u201399.","journal-title":"Cancer"},{"issue":"3","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.critrevonc.2006.06.006","volume":"60","author":"SMH Alibhai","year":"2006","unstructured":"Alibhai SMH, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60(3):201\u201315.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1843_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"1843_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","volume":"175","author":"MR Smith","year":"2006","unstructured":"Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175(1):136\u20139. discussion 139.","journal-title":"J Urol"},{"issue":"31","key":"1843_CR12","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897\u2013903.","journal-title":"J Clin Oncol"},{"issue":"9156","key":"1843_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878\u201382.","journal-title":"Lancet"},{"issue":"5","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513\u201321.","journal-title":"JAMA"},{"issue":"6","key":"1843_CR15","first-page":"4908","volume":"16","author":"Y-K Lau","year":"2009","unstructured":"Lau Y-K, Lee E, Prior HJ, Lix LM, Metge CJ, Leslie WD. Fracture risk in androgen deprivation therapy: a Canadian population based analysis. Can J Urol. 2009;16(6):4908\u201314.","journal-title":"Can J Urol"},{"issue":"6","key":"1843_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00198-004-1799-7","volume":"16","author":"AM Lopez","year":"2005","unstructured":"Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16(6):707\u201311.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1843_CR17","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","volume":"184","author":"SMH Alibhai","year":"2010","unstructured":"Alibhai SMH, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184(3):918\u201324.","journal-title":"J Urol"},{"issue":"11","key":"1843_CR18","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00198-009-0840-2","volume":"20","author":"JR Curtis","year":"2009","unstructured":"Curtis JR, Taylor AJ, Matthews RS, Ray MN, Becker DJ, Gary LC, et al. \u201cPathologic\u201d fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int. 2009;20(11):1969\u201372.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1843_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1464-410X.2007.07163.x","volume":"100","author":"B Abrahamsen","year":"2007","unstructured":"Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007;100(4):749\u201354.","journal-title":"BJU Int"},{"issue":"4","key":"1843_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1017\/S0007114508207221","volume":"102","author":"EC Rush","year":"2009","unstructured":"Rush EC, Freitas I, Plank LD. Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr. 2009;102(4):632\u201341.","journal-title":"Br J Nutr"},{"key":"1843_CR21","first-page":"1207","volume":"117","author":"E Rush","year":"2004","unstructured":"Rush E, Plank L, Chandu V, Laulu M, Simmons D, Swinburn B, et al. Body size, body composition, and fat distribution: a comparison of young New Zealand men of European, Pacific Island, and Asian Indian ethnicities. N Z Med J. 2004;117:1207.","journal-title":"N Z Med J"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bone.2015.01.015","volume":"74","author":"K Zhu","year":"2015","unstructured":"Zhu K, Hunter M, James A, Lim EM, Walsh JP. Associations between body mass index, lean and fat body mass and bone mineral density in middle-aged Australians: The Busselton Healthy Ageing Study. Bone. 2015;74:146\u201352.","journal-title":"Bone"},{"issue":"11","key":"1843_CR23","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.ejca.2012.01.035","volume":"48","author":"A Thorstenson","year":"2012","unstructured":"Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672\u201381.","journal-title":"Eur J Cancer"},{"issue":"13","key":"1843_CR24","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","volume":"22","author":"MR Smith","year":"2004","unstructured":"Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22(13):2546\u201353.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1843_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","volume":"104","author":"VK Wadhwa","year":"2009","unstructured":"Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104(6):800\u20135.","journal-title":"BJU Int"},{"issue":"6 Pt 1","key":"1843_CR26","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","volume":"171","author":"PR Sieber","year":"2004","unstructured":"Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150\u00a0mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004;171(6 Pt 1):2272\u20136.","journal-title":"J Urol"},{"issue":"1","key":"1843_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MAP, Senra MD, Wroclawski ML, Fonseca FLA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36\u201344.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"1843_CR28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bju.12497","volume":"114","author":"JW Denham","year":"2014","unstructured":"Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer. BJU Int. 2014;114(3):344\u201353.","journal-title":"BJU Int"},{"issue":"10","key":"1843_CR29","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","volume":"15","author":"JW Denham","year":"2014","unstructured":"Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014;15(10):1076\u201389.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1843_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jbmr.1749","volume":"28","author":"C Morrissey","year":"2013","unstructured":"Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, et al. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res. 2013;28(2):333\u201340.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1843_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380\u201390.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1843_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pds.2258","volume":"21","author":"JL Beebe-Dimmer","year":"2012","unstructured":"Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, et al. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf. 2012;21(1):70\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1843-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1843-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1843-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:14:54Z","timestamp":1718169294000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1843-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1843-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]},"article-number":"837"}}